Earn Money Nepal

Vision Lumbini Urja Company Limited Opens IPO Subscription with Additional Units for the Public

Vision Lumbini Urja Company Limited is set to initiate the issuance of its 20,75,285 unit Initial Public Offering (IPO) shares starting on the 16th Kartik, 2080. The closing date for the early subscription period for these shares is the 20th Kartik, with the option for an extension up to the 1st Mangsir, 2080, if the issue is not fully subscribed.

Previously, the company had allocated 19,12,500 unit shares to individuals affected by the company’s projects in Kaski District. However, only 14,24,590 units were allotted to eligible applicants. Consequently, the remaining 4,87,910 units of unsubscribed shares from project-affected locals have been combined with the 19,12,500 units to create a total of 24,00,410 units available to the general public.

Of these total shares, 191,250 units have already been issued and assigned to Nepalese citizens working abroad, 95,625 units are earmarked for mutual funds, while 38,250 units are reserved for company employees. The remaining 20,75,285 units are open for general public subscription.

The per-share price for these shares is set at Rs. 100. Muktinath Capital Limited is entrusted with the role of the issue manager. Investors can apply for a minimum of 10 units, with an upper limit of 380,000 units.

ICRA Nepal has reaffirmed its credit ratings for Vision Lumbini Urja Company Limited, maintaining a long-term rating of [ICRANP] LBB- and a short-term rating of [ICRANP] A4 for the company’s loan limits.

Vision Lumbini Urja Company Limited is actively engaged in the development of the 25-MW Seti Nadi Hydroelectric Project, located in the Machhapuchchhre rural municipality of Kaski District in the Gandaki Province of Nepal. The project is classified as a run-of-the-river (R-o-R) type and is designed to operate at a 44.5% probability of exceedance. This information outlines the details of the upcoming IPO and the company’s project endeavors.


Please enter your comment!
Please enter your name here